AKT1 and neoplasm: Various mechanisms of MEKi resistance have been elucidated in previous studies (16–21), including kinome reprogramming, tumor microenvironment alterations, and activation of resistance pathways including PI3K/AKT, MAPK, and STAT3 (22–24).